129 related articles for article (PubMed ID: 33507729)
21. Angiopep-2-Functionalized Lipid Cubosomes for Blood-Brain Barrier Crossing and Glioblastoma Treatment.
Cai X; Refaat A; Gan PY; Fan B; Yu H; Thang SH; Drummond CJ; Voelcker NH; Tran N; Zhai J
ACS Appl Mater Interfaces; 2024 Mar; 16(10):12161-12174. PubMed ID: 38416873
[TBL] [Abstract][Full Text] [Related]
22. Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
Arcella A; Palchetti S; Digiacomo L; Pozzi D; Capriotti AL; Frati L; Oliva MA; Tsaouli G; Rota R; Screpanti I; Mahmoudi M; Caracciolo G
ACS Chem Neurosci; 2018 Dec; 9(12):3166-3174. PubMed ID: 30015470
[TBL] [Abstract][Full Text] [Related]
23. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
24. Scaffolds biomimicking macrophages for a glioblastoma NIR-Ib imaging guided photothermal therapeutic strategy by crossing Blood-Brain Barrier.
Lai J; Deng G; Sun Z; Peng X; Li J; Gong P; Zhang P; Cai L
Biomaterials; 2019 Aug; 211():48-56. PubMed ID: 31085358
[TBL] [Abstract][Full Text] [Related]
25. Neutrophil Delivered Hollow Titania Covered Persistent Luminescent Nanosensitizer for Ultrosound Augmented Chemo/Immuno Glioblastoma Therapy.
Li Y; Teng X; Wang Y; Yang C; Yan X; Li J
Adv Sci (Weinh); 2021 Sep; 8(17):e2004381. PubMed ID: 34196474
[TBL] [Abstract][Full Text] [Related]
26. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
27. Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy.
Pellosi DS; Paula LB; de Melo MT; Tedesco AC
Mol Pharm; 2019 Mar; 16(3):1009-1024. PubMed ID: 30698450
[TBL] [Abstract][Full Text] [Related]
28. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
29. Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma.
Zeng X; Wang Q; Tan X; Jia L; Li Y; Hu M; Zhang Z; Bai X; Zhu Y; Yang X
J Nanobiotechnology; 2019 Apr; 17(1):47. PubMed ID: 30935403
[TBL] [Abstract][Full Text] [Related]
30. Persistent HCMV infection of a glioblastoma cell line contributes to the development of resistance to temozolomide.
Singh P; Neumann DM
Virus Res; 2020 Jan; 276():197829. PubMed ID: 31790777
[TBL] [Abstract][Full Text] [Related]
31. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
32. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
[TBL] [Abstract][Full Text] [Related]
33. Pam
Megías J; Martínez A; San-Miguel T; Gil-Benso R; Muñoz-Hidalgo L; Albert-Bellver D; Carratalá A; Gozalbo D; López-Ginés C; Gil ML; Cerdá-Nicolás M
Invest New Drugs; 2020 Apr; 38(2):299-310. PubMed ID: 31076963
[TBL] [Abstract][Full Text] [Related]
34. Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line.
Abbaszade Z; Bagca BG; Avci CB
Gene; 2021 Apr; 776():145445. PubMed ID: 33484758
[TBL] [Abstract][Full Text] [Related]
35. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
He Y; Kaina B
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
[TBL] [Abstract][Full Text] [Related]
36. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
37. Synergistic anticancer effect of acteoside and temozolomide-based glioblastoma chemotherapy.
Hwang TW; Kim DH; Kim DB; Jang TW; Kim GH; Moon M; Yoon KA; Choi DE; Park JH; Kim JJ
Int J Mol Med; 2019 Mar; 43(3):1478-1486. PubMed ID: 30664150
[TBL] [Abstract][Full Text] [Related]
38. Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Zhang Z; Wang Y; Chen J; Tan Q; Xie C; Li C; Zhan W; Wang M
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1289-1296. PubMed ID: 27832326
[TBL] [Abstract][Full Text] [Related]
39. A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise.
Tian M; Xing R; Guan J; Yang B; Zhao X; Yang J; Zhan C; Zhang S
Nano Lett; 2021 Jun; 21(12):5158-5166. PubMed ID: 34097422
[TBL] [Abstract][Full Text] [Related]
40. Lnc-TALC promotes O
Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
